Treatment of cancer with heavy charged particles.
A clinical radiotherapeutic trial using heavy charged particles in the treatment of human cancers has accrued over 400 patients since 1975, 378 of whom were treated with particles and 28 with low LET photons as control patients. Heavy charged particle radiotherapy offers the potential advantages of improved dose localization and/or enhanced biologic effect, depending on particle selected for treatment. Target sites have included selected head and neck tumors, ocular melanomata, malignant gliomata of the brain, carcinoma of the esophagus, carcinoma of the stomach, carcinoma of the pancreas, selected juxtaspinal tumors and other locally advanced, unresectable tumors. A Phase III prospective clinical trial has been started in carcinoma of the pancreas using helium ions. Phase I-II studies are underway with heavier particles such as carbon, neon and argon ions in order to prepare for prospective Phase III trials. Silicon ions are also under consideration for clinical trial. These studies are supported by the United States Department of Energy and National Institutes of Health.
D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy; D002986:Clinical Trials as Topic; D004601:Elementary Particles; D004938:Esophageal Neoplasms / Q000532:radiotherapy; D005134:Eye Neoplasms / Q000532:radiotherapy; D005260:Female; D006371:Helium; D006801:Humans; D007477:Ions; D008297:Male; D008545:Melanoma / Q000532:radiotherapy; D008875:Middle Aged; D009369:Neoplasms / Q000532:radiotherapy*; D010190:Pancreatic Neoplasms / Q000532:radiotherapy; D011882:Radiotherapy, High-Energy / Q000009:adverse effects; D012888:Skull Neoplasms / Q000532:radiotherapy; D013125:Spinal Neoplasms / Q000532:radiotherapy
D007477:Ions; D006371:Helium